ARA-C AND AMSA FOR TREATMENT OF RELAPSED AND REFRACTORY ACUTE MYELOID-LEUKEMIA

被引：0
|
作者：
JAGER, U
LECHNER, K
SCHWARZINGER, I
BETTELHEIM, P
BOGNAR, H
GEISSLER, K
HAAS, O
HINTERBERGER, W
KOS, M
LEITHA, T
NEUMANN, E
PANZER, S
POLLAK, C
机构：
[1] VIENNA UNIV,DEPT MED 1,A-1010 VIENNA,AUSTRIA
[2] ST ANNA CHILDRENS HOSP,VIENNA,AUSTRIA
来源：
BLUT | 1986年 / 53卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：145 / 145
页数：1
相关论文
共 50 条
  • [41] MIRROS: An ongoing randomized phase 3 trial of idasanutlin plus ARA-C in patients with relapsed or refractory acute myeloid leukemia.
    Montesinos, Pau
    Esteve, Jordi
    Konopleva, Marina
    Martinelli, Giovanni
    Ottmann, Oliver
    Rodriguez-Veiga, Rebeca
    Rollig, Christoph
    Wei, Andrew
    Vey, Norbert
    Chiu, Idy
    Monnet, Annabelle
    Ott, Marion Gabriele
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Treatment of Relapsed/Refractory Acute Myeloid Leukemia
    Bose, Prithviraj
    Vachhani, Pankit
    Cortes, Jorge E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (03)
  • [43] Treatment of Relapsed/Refractory Acute Myeloid Leukemia
    Prithviraj Bose
    Pankit Vachhani
    Jorge E. Cortes
    Current Treatment Options in Oncology, 2017, 18
  • [44] ROFERON-A IN COMBINATION WITH ARA-C AS A 1ST-LINE TREATMENT IN CHRONIC MYELOID-LEUKEMIA
    ARTHUR, CK
    BRITISH JOURNAL OF HAEMATOLOGY, 1992, 82 (01) : 284 - 285
  • [45] Phase II study of Idarubicine, Fludarabine, ARA-C, and G-CSF (IDA-Flag) for treatment of refractory, relapsed or secondary acute myeloid leukemia
    Steinmetz, HT
    Staib, P
    Glasmacher, A
    Neufang, A
    Katay, I
    Diehl, V
    Wickramanayake, PD
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 821 - 821
  • [46] INTERMEDIATE AND HIGH-DOSE ARA-C AND M-AMSA FOR REMISSION INDUCTION AND CONSOLIDATION TREATMENT OF PATIENTS WITH ACUTE MYELOID-LEUKEMIA - AN EORTC LEUKEMIA COOPERATIVE GROUP PHASE-II STUDY
    WILLEMZE, R
    JAGER, U
    JEHN, U
    STRYCKMANS, P
    BURY, J
    SUCIU, S
    SOLBU, G
    ZITTOUN, R
    BURGHOUTS, J
    LOWENBERG, B
    ABELS, J
    CAUCHIE, C
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (11): : 1721 - 1725
  • [47] CONCORDANT CHANGES OF PYRIMIDINE METABOLISM IN BLASTS OF 2 CASES OF ACUTE MYELOID-LEUKEMIA AFTER REPEATED TREATMENT WITH ARA-C INVIVO
    CHIBA, P
    TIHAN, T
    SZEKERES, T
    SALAMON, J
    KRAUPP, M
    EHER, R
    KOLLER, U
    KNAPP, W
    LEUKEMIA, 1990, 4 (11) : 761 - 765
  • [48] Phase I study of UCN-01 and ara-C for patients with refractory or relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cortes, J
    Plunkett, WK
    Estey, EH
    Keating, MJ
    Madden, T
    Sampath, D
    Faderl, S
    Beran, M
    Dancey, J
    Kantarjian, HM
    BLOOD, 2001, 98 (11) : 211B - 211B
  • [49] COMBINED ANTILEUKEMIC ACTIVITY OF PIXY-321 AND ARA-C AGAINST HUMAN ACUTE MYELOID-LEUKEMIA CELLS
    TANG, C
    HUANG, Y
    PONNATHPUR, VS
    RAY, S
    MAHONEY, ME
    BULLOCK, G
    IBRADO, AM
    BHALLA, K
    LEUKEMIA & LYMPHOMA, 1994, 15 (5-6) : 445 - 451
  • [50] PRONOSTIC VALUE OF INVITRO UPTAKE AND RETENTION OF CYTOSINE-ARABINOSIDE (ARA-C) IN ACUTE MYELOID-LEUKEMIA (AML)
    MARIE, JP
    ZITTOU, R
    DELANIAN, S
    SUBERVILLE, AM
    THEVENIN, D
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 208 - 208
12345